Document is current
Any future updates will be listed below
-
Authors
Grünewald, Thomas GP https://orcid.org/0000-0003-0920-7377
Alonso, Marta https://orcid.org/0000-0002-7520-7351
Avnet, Sofia
Banito, Ana
Burdach, Stefan
Cidre‐Aranaz, Florencia https://orcid.org/0000-0002-0246-7179
Di Pompo, Gemma
Distel, Martin
Dorado‐Garcia, Heathcliff
Garcia‐Castro, Javier
González‐González, Laura
Grigoriadis, Agamemnon E
Kasan, Merve
Koelsche, Christian
Krumbholz, Manuela
Lecanda, Fernando
Lemma, Silvia
Longo, Dario L
Madrigal‐Esquivel, Claudia
Morales‐Molina, Álvaro
Musa, Julian
Ohmura, Shunya
Ory, Benjamin
Pereira‐Silva, Miguel
Perut, Francesca
Rodriguez, Rene https://orcid.org/0000-0002-0768-7306
Seeling, Carolin
Al Shaaili, Nada
Shaabani, Shabnam
Shiavone, Kristina
Sinha, Snehadri
Tomazou, Eleni M
Trautmann, Marcel https://orcid.org/0000-0002-5842-1196
Vela, Maria
Versleijen‐Jonkers, Yvonne MH
Visgauss, Julia
Zalacain, Marta
Schober, Sebastian J
Lissat, Andrej
English, William R
Baldini, Nicola https://orcid.org/0000-0003-2228-3833
Heymann, Dominique https://orcid.org/0000-0001-7777-0669
- License Information
-
More Information
Article History
Received: 9 July 2019
Revised: 20 July 2020
Accepted: 24 July 2020
First Online: 13 October 2020
Conflict of interest
: Marta Alonso has obtained research grant from DNAtrix. Stefan Budach has an ownership interest in PDL BioPharma and has had US and EU intellectual properties in gene expression analysis. He served as consultant to EOS Biotechnology Inc. and serves as advisor to Bayer AG and Swedish Orphan Biovitrum AB. Dominique Heymann has an ownership interest in Atlanta SAS (Saint‐Herblain, France).
